The impact of topical cyclosporine A emulsion 0.05% on the outcomes of patients with keratoconjunctivitis sicca

Current Medical Research and Opinion

Volumn 21, Issue 7, 2005, Pages 1057-1063

  Stonecipher, Karl ^a   Perry, Henry D ^b,c   Gross, Robert H ^d,e   Kerney, Donna L ^f  

^a Southeastern Laser and Refractive Center   (United States)

^b OPHTHALMIC CONSULTANTS OF LONG ISLAND   (United States)

^c WEILL CORNELL MEDICAL COLLEGE   (United States)

^d Cornea Consultants of Arizona ^*  (United States)

^e Donor Network of Arizona   (United States)

^f InfoMedics Inc   (United States)

Author keywords

Cyclosporine ophthalmic emulsion; Dry eye; Keratoconjunctivitis sicca

Indexed keywords

AGENTS ACTING ON THE EYE; ARTIFICIAL TEAR; CYCLOSPORIN A;

ADULT; AGED; ARTICLE; DAILY LIFE ACTIVITY; DISEASE SEVERITY; DRUG EFFICACY; DRUG FORMULATION; DRY EYE; EMULSION; FEMALE; HUMAN; KERATOCONJUNCTIVITIS SICCA; MAJOR CLINICAL STUDY; MALE; PATIENT SATISFACTION; SYMPTOMATOLOGY; TREATMENT OUTCOME;

ADMINISTRATION, TOPICAL; CYCLOSPORINE; EMULSIONS; FEMALE; HUMANS; KERATOCONJUNCTIVITIS SICCA; MALE; MIDDLE AGED; TREATMENT OUTCOME;

EID: 22744454056     PISSN: 03007995     EISSN: None     Source Type: Journal    
DOI: 10.1185/030079905X50615     Document Type: Article

References (14)

1. Pflugfelder SC. Antiinflammatory therapy for dry eye. Am J Ophthalmol 2004;137(2):337-42
2. Wilson SE. Inflammation: a unifying theory for the origin of dry eye. Managed Care 2003;12(Suppl):14-19
3. Perry HD, Donnenfeld ED. Dry eye diagnosis and management in 2004. Curr Opin Ophthalmol 2004;15(4):299-304
4. Perry HD, Donnenfeld ED, Perry AR, et al. Evaluation of topical cyclosporine A 0.05% for the treatment of dry eye disease. Presented in part as a paper at the 2004 American Academy of Ophthalmology Annual Meeting, New Orleans, Louisiana, USA
5. Schein OD, Tielsch JM, Munoz B, et al. Relation between signs and symptoms of dry eye in the elderly. A population-based perspective. Ophthalmology 1997;104:1395-401
6. Schaumberg DA, Sullivan DA, et al. Prevalence of dry eye syndrome among US women. Am J Ophthalmol 2003;136: 318-26
7. Begley CG, Chalmers RL, Abetz L, et al. The relationship between habitual patient-reported symptoms and clinical signs among patients with dry eye of varying severity. Invest Ophthalmol Vis Sci 2003;44:4753-61
8. O'Brien PD, Collum LMT. Dry eye: diagnosis and current treatment strategies. Curr Allergy Asthma Rep 2004;4:314-9
9. Perry HD, Donnefeld ED. Topical 0.05% cyclosporin A in the treatment of dry eye. Expert Opin Pharmacother 2004;5(10):2099-107
10. Sall K, Stevenson OD, Mundorf TK, Reis BL. Two multicenter, randomized studies of the efficacy and safety of cyclosporine ophthalmic emulsion in moderate to severe dry eye disease [CsA Phase 3 Study Group]. Ophthalmology 2000;107:631-9
11. Stevenson D, Tauber J, Reis BL. Efficacy and safety of cyclosporine A ophthalmic emulsion in the treatment of moderate-to-severe dry eye disease: a dose-ranging randomized trial [The Cyclosporin A Phase 2 Study Group]. Ophthalmology 2000;107:967-74
12. Nichols KK, Mitchell GL, Zadnik K. The repeatability of clinical measurements of dry eye. Cornea 2004;23:272-85
13. Turner K, Pflugfelder SC, et al. Interleukin-6 levels in the conjunctival epithelium of patients with dry eye disease treated with cyclosporine ophthalmic emulsion. Cornea 2000;19:492-6
14. Tauber J. A dose-ranging clinical trial to assess the safety and efficacy of cyclosporine ophthalmic emulsion in patients with keratoconjunctivitis sicca [The Cyclosporine Study Group]. Adv Exp Med Biol 1998;438:969-72